JDIT 2014 0620 001.pdf
Journal of Diagnostic Imaging in Therapy. 2014; 1(1): 1-19
Grachev et al.
Peer-Reviewed Open Access
JOURNAL OF DIAGNOSTIC IMAGING IN THERAPY
Journal homepage: www.openmedscience.com
Quantitative in vivo Imaging of Adenosine A2A Receptors in the
Human Brain Using 11C-SCH442416 PET: A Pilot Study
Igor D. Grachev 1,*, Miroslava Doder 2, †, David J. Brooks 2,3, Rainer Hinz4
Schering-Plough Research Institute, Kenilworth, NJ, USA
MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial
College, London, UK
Hammersmith Imanet Ltd., GE Healthcare, Hammersmith Hospital, London, UK
Wolfson Molecular Imaging Centre, University of Manchester, UK
* Author to whom correspondence should be addressed
Igor Grachev, M.D., Ph.D.
Independent R&D Pharmaceutical Consultant
T: +1 732 642 7773
C-SCH442416 was reported in preclinical studies with rodents and primates to be the first
nonxanthine radioligand suitable for the in vivo imaging of adenosine A2A receptors with positron
emission tomography (PET). The aim of the present work was to investigate the suitability of 11CSCH442416 for the in vivo quantification of A2A receptors in human brain.
Methods: Five male healthy subjects were scanned with 364 MBq bolus injections of 11CSCH442416. 90 minutes of dynamic PET emission data were acquired, and arterial blood samples
ISSN: 2057-3782 (Online)